David M. Nanus, MD
New therapeutic options for patients with renal cell carcinoma (RCC) have developed rapidly, and researchers are hoping to further capitalize on these advances.
at the meeting, Nanus highlighted the key points of his lecture.
OncLive: Please provide an overview on your presentation.
As we’ve developed more effective therapies for patients with advanced kidney cancer, we want to determine the role of these treatments in earlier stages of disease for patients who still have their primary tumor in place. Similar to any solid tumor, when we see a therapy that works in later stages of disease, the question becomes can you move that treatment up to an earlier stage and have a benefit in preventing relapse or improving outcomes in patients.
... to read the full story